YTHDF2 regulates RNA degradation (Chen et al., 2022[28]; Hsu et al., 2017[81]), and YTHDF2 is a oncogenic gene in most cancer types (Bai et al., 2023[3]; Jin et al., 2024[111]; Jiang et al., 2024[107]; Li et al., 2020[128]; Zhang et al., 2023[343]), however, it exerted both carcinogenic and anticarcinogenic effects in gastric cancer (Fang et al., 2023[55]; Ren et al., 2024[198]; Zhou et al., 2023[366]), hepatocellular carcinoma (Yang et al., 2023[319]; Wen et al., 2024[287]; Hou et al., 2019[78]; Zhong et al., 2019[360]), and pancreatic cancers (Tan et al., 2022[233]; Guo et al., 2020[66]). This evidence concerns the gene YTHDF2 and hepatocellular carcinoma.